Budget impact analysis of the introduction of Rosiglitazone in the treatment of type-2 diabetes. The Italian NHS perspective

被引：0

作者：

Novelli, M ^{[1
]}

Avallone, A ^{[1
]}

Frizzo, V ^{[1
]}

Bamfi, F ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Verona, VR, Italy

来源：

VALUE IN HEALTH | 2005年 / 8卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)67631-0

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A158 / A158

页数：1

共 50 条

[21] Rosiglitazone is effective and well tolerated in patients ≥65 years with type 2 diabetes.
Beebe, KL
DIABETOLOGIA, 1999, 42 : A227 - A227
[22] Rosiglitazone in combination with metformin effectively reduces hyperglycemia in patients with type 2 diabetes.
Fonseca, V
Biswas, N
Salzman, A
DIABETOLOGIA, 1999, 42 : A230 - A230
[23] THE BUDGET IMPACT ANALYSIS OF VILDAGLIPTIN IN TYPE 2 DIABETES IN POLAND
Walczak, J.
Nogas, G.
Gebus, E.
Pawlik, D.
Pacocha, K.
VALUE IN HEALTH, 2009, 12 (07) : A403 - A404
[24] Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt
Elsisi, Gihan Hamdy
Anwar, Mohammed Moustapha
Khattab, Mohamed
Elebrashy, Ibrahim
Wafa, Alaa
Elhadad, Hemat
Awad, Mohamad
Carapinha, Joao L.
JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (08) : 908 - 914
[25] Is type-2 adult diabetes a variety of idiohypophyseal diabetes.: A proposition that opens alternatives
Fernández, LV
REVISTA MEDICA DE CHILE, 2000, 128 (03) : 330 - 337
[26] EVALUATION OF THE PHARMACY BUDGET IMPACT OF ALOGLIPTIN PLUS PIOGLITAZONE FIXED DOSE COMBINATION IN THE TREATMENT OF TYPE-2 DIABETES MELLITUS
Bron, M.
Ferrufino, C. P.
Samyshkin, Y.
Munakata, J.
VALUE IN HEALTH, 2013, 16 (03) : A160 - A160
[27] Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand
Permsuwan, Unchalee
Deerochanawong, Chaicharn
FRONTIERS IN PUBLIC HEALTH, 2025, 12
[28] Exenatide trials for the treatment of type 2 diabetes.
Fernandez Lando, Laura
Casellini, Carolina M.
MEDICINA-BUENOS AIRES, 2009, 69 (04) : 447 - 457
[29] A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of Type-2 diabetes mellitus in the UK
Tilden, D
Mariz, S
Diamantopoulos, A
O'Bryan-Tear, G
VALUE IN HEALTH, 2005, 8 (06) : A164 - A164
[30] Cost-effectiveness in Germany of rosiglitazone-metformin combination in Type 2 diabetes.
Bagust, A
Shearer, A
Schoeffski, O
Reitberger, U
Goertz, A
Behrens, M
DIABETOLOGIA, 2003, 46 : A444 - A444

← 1 2 3 4 5 →